As demonstrated in the prisoner study on Giardia and the mucosal barrier, healthy first-line immunity goes a long way toward preventing infections.
Interferon-alfa may be considered in young patients who do not have advanced liver disease and do not wish to be on long-term treatment. Interferon-alfa is not appropriate for people with cirrhosis who have liver failure or for people who have a recurrence of hepatitis after liver transplantation.
ACP Medicine: "Allergic Rhinitis, Conjunctivitis, and Sinusitis."
© Australian Indigenous Health InfoNet 2015
This product, excluding the Australian Indigenous Health InfoNet logo, artwork, and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY-NC-ND (CC BY-NC-ND ) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures.
© 2014 Attendance Works / All Rights Reserved.